$2.11
1.93%
Nasdaq, Sep 30, 04:00 pm EDT. Closed.
ISIN
US49720K1016
Symbol
HURA

Kintara Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Kintara Therapeutics Inc Classifications & Recommendation

Buy
90%
Hold
10%

Kintara Therapeutics Inc Price Target

Target Price $8.16
Price $2.10
Potential
Number of Estimates 7
7 Analysts have issued a price target Kintara Therapeutics Inc 2027 . The average Kintara Therapeutics Inc target price is $8.16. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend Kintara Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kintara Therapeutics Inc stock has an average upside potential 2027 of . Most analysts recommend the Kintara Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -0.63 -0.54
47.93% 14.29%
P/E negative

7 Analysts have issued a Kintara Therapeutics Inc forecast for earnings per share. The average Kintara Therapeutics Inc EPS is

$-0.54
unlock
. This is
14.89% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.53 12.77%
unlock
, the lowest is
$-0.56 19.15%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.63 47.93%
2026
$-0.54 14.29%
unlock
2027
$-0.59 9.26%
unlock
2028
$-0.55 6.78%
unlock
2029
$0.95 272.73%
unlock
2030
$2.01 111.58%
unlock
2031
$4.10 103.98%
unlock
2032
$5.08 23.90%
unlock
2033
$6.20 22.05%
unlock

P/E ratio

Current -4.40 55.76%
2026
-3.81 13.49%
unlock
2027
-3.53 7.35%
unlock
2028
-3.77 6.80%
unlock

Current Kintara Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Citizens
Locked
➜
Locked
Locked Aug 18 2026
Citizens
Locked
➜
Locked
Locked Apr 27 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Feb 03 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Jan 09 2026
Maxim Group
Locked
➜
Locked
Locked Nov 14 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked May 16 2025
HC Wainwright & Co.
Locked
➜
Locked
Locked Apr 03 2025
Analyst Rating Date
Locked
Citizens:
Locked
➜
Locked
Aug 18 2026
Locked
Citizens:
Locked
➜
Locked
Apr 27 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Feb 03 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jan 09 2026
Locked
Maxim Group:
Locked
➜
Locked
Nov 14 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
May 16 2025
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Apr 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today